These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 3269674)

  • 21. Treadmill exercise promotes cyclic alterations in coronary blood flow in dogs with coronary artery stenoses and endothelial injury.
    Eidt JF; Ashton J; Golino P; McNatt J; Buja LM; Willerson JT
    J Clin Invest; 1989 Aug; 84(2):517-27. PubMed ID: 2760199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.
    Fitzgerald DJ; Doran J; Jackson E; FitzGerald GA
    J Clin Invest; 1986 Feb; 77(2):496-502. PubMed ID: 3003161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
    Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
    Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental evaluation of coronary thrombodynamics and effects of pharmacological interventions in acute coronary syndromes.
    Tomoda H
    Jpn Circ J; 1992 Nov; 56(11):1184-90. PubMed ID: 1453544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis.
    Pratico D; Murphy NP; Fitzgerald DJ
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1178-85. PubMed ID: 9190851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of serotonin in thrombogenesis.
    De Clerck F
    Clin Physiol Biochem; 1990; 8 Suppl 3():40-9. PubMed ID: 1966729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet aggregation induced in vitro by rabbit plasma clot-associated thrombin, and its inhibition by thrombin inhibitors.
    Gandossi E; Lunven C; Gauffeny C; Roome NO; Berry CN
    Thromb Haemost; 1998 Nov; 80(5):840-4. PubMed ID: 9843181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative effects of cigarette smoke and ethanol on acute platelet thrombus formation in stenosed canine coronary arteries.
    Keller JW; Folts JD
    Cardiovasc Res; 1988 Jan; 22(1):73-8. PubMed ID: 3167932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulating platelet function with selective thrombin inhibitors.
    Verstraete M
    Haemostasis; 1996 Oct; 26 Suppl 4():70-7. PubMed ID: 8979113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor.
    Cella G; Girolami A; Sasahara AA
    Circulation; 1999 Jun; 99(25):3323. PubMed ID: 10385510
    [No Abstract]   [Full Text] [Related]  

  • 33. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD; Witzke C; Colon-Hernandez P; Guerrero JL; Bloch KD; Semigran MJ
    J Am Coll Cardiol; 2006 Apr; 47(7):1471-7. PubMed ID: 16580539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of thrombin-induced platelet adherence to vascular cells by synthetic thrombin inhibitor No. 805.
    Czervionke RL; Hoak JC; Haycraft DL; Fry GL
    Trans Assoc Am Physicians; 1983; 96():271-7. PubMed ID: 6679956
    [No Abstract]   [Full Text] [Related]  

  • 35. [Redistribution of the coronary blood flow, functional improvement of the ischemic myocardium and reduction of the size of an experimental infarction by molsidomine].
    Berdeaux A; Giudicelli JF
    Ann Cardiol Angeiol (Paris); 1983 Dec; 32(8):511-5. PubMed ID: 6364947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of 3-methoxycyproheptadine in a canine model of coronary thrombosis.
    Bush LR; Remy DC
    J Pharmacol Exp Ther; 1988 Nov; 247(2):796-802. PubMed ID: 3183974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic effects of the thromboxane A2 antagonist, SQ 28,668, in vitro and in the coronary circulation in vivo.
    Ogletree ML; Harris DN; Heran CL; Phillips MB; Michel IM; Goldenberg HJ
    Eicosanoids; 1988; 1(2):85-91. PubMed ID: 2856188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Xanthine oxidase mediates cyclic flow variations in a canine model of coronary arterial thrombosis.
    Kuwano K; Ikeda H; Oda T; Nakayama H; Koga Y; Toshima H; Imaizumi T
    Am J Physiol; 1996 Jun; 270(6 Pt 2):H1993-9. PubMed ID: 8764249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the selective thromboxane synthetase inhibitor, dazoxiben, on cyclic flow variations in stenosed canine coronary arteries.
    Bush LR; Campbell WB; Tilton GD; Buja LM; Willerson JT
    Trans Assoc Am Physicians; 1983; 96():103-12. PubMed ID: 6687298
    [No Abstract]   [Full Text] [Related]  

  • 40. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
    J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.